An observational study on the expression levels of MDM2 and MDMX proteins, and associated effects on P53 in a series of human liposarcomas

BMC Clinical Pathology

Volumn 13, Issue 1, 2013, Pages

  Touqan, Nader ^a,b   Diggle, Christine P ^a   Verghese, Edlo T ^a   Perry, Sarah ^a   Horgan, Kieran ^b   Merchant, William ^b   Anwar, Rashida ^a   Markham, Alexander F ^a,b   Carr, Ian M ^a   Achuthan, Rajgopal ^b  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Liposarcoma; MDM2; MDMX; P53; Targeted therapy

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53;

ARTICLE; CASE STUDY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; P53 GENE; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; SOMATIC MUTATION; TUMOR GENE;

EID: 84889982509     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-13-32     Document Type: Article

References (40)

1. Guidelines for the management of soft tissue sarcomas. Grimer R, Judson I, Peake D, Seddon B, Sarcoma 2010 2010 506182 20634933
2. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. Teodoro JG, Evans SK, Green MR, J Mol Med 2007 85 11 1175 1186 10.1007/s00109-007-0221-2 17589818 (Pubitemid 47622219)
3. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Crozat A, Aman P, Mandahl N, Ron D, Nature 1993 363 6430 640 644 10.1038/363640a0 8510758 (Pubitemid 23227627)
4. Liposarcoma: molecular genetics and therapeutics. Conyers R, Young S, Thomas DM, Sarcoma 2011 2011 483154 21253554
5. Mutational spectrum of p53 mutations in primary breast and ovarian tumors. Feki A, Irminger-Finger I, Crit Rev Oncol Hematol 2004 52 2 103 116 10.1016/j.critrevonc.2004.07.002 15501075 (Pubitemid 39419493)
6. Soft tissue sarcomas and p53 mutations. Taubert H, Meye A, Wurl P, Mol Med 1998 4 6 365 372 10780879 (Pubitemid 28387895)
7. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B, Cancer Res 1993 53 10 2231 2234 8387391 (Pubitemid 23156805)
8. Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation. Wang YV, Wade M, Wong E, Li YC, Rodewald LW, Wahl GM, Proc Natl Acad Sci U S A 2007 104 30 12365 12370 10.1073/pnas.0701497104 17640893 (Pubitemid 47206143)
9. Targeting the MDM2-p53 interaction for cancer therapy. Shangary S, Wang S, Clin Cancer Res 2008 14 17 5318 5324 10.1158/1078-0432.CCR-07-5136 18765522
10. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma. Dei Tos AP, Doglioni C, Piccinin S, Maestro R, Mentzel T, Barbareschi M, Boiocchi M, Fletcher CD, J Pathol 1997 181 1 8 13 10.1002/(SICI)1096-9896(199701)181:1<8::AID-PATH700>3.0.CO;2-# 9071997 (Pubitemid 27099768)
11. MDM2 mRNA level is a prognostic factor in soft tissue sarcoma. Taubert H, Koehler T, Meye A, Bartel F, Lautenschlager C, Borchert S, Bache M, Schmidt H, Wurl P, Mol Med 2000 6 1 50 59 10803408
12. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. Pilotti GT, Lavarino C, J Pathol 1997 181 14 24 10.1002/(SICI)1096-9896(199701)181:1<14::AID- PATH730>3.0.CO;2-O 9071998 (Pubitemid 27099769)
13. MDMX: a novel p53-binding protein with some functional properties of MDM2. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ, et al. EMBO J 1996 15 19 5349 5357 8895579 (Pubitemid 26336217)
14. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE, J Mol Biol 2006 363 2 433 450 10.1016/j.jmb.2006.08.027 16965791 (Pubitemid 44436256)
15. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM, Cancer Cell 2006 9 4 273 285 10.1016/j.ccr.2006.03.014 16616333
16. MdmX protects p53 from Mdm2-mediated degradation. Jackson MW, Berberich SJ, Mol Cell Biol 2000 20 3 1001 1007 10.1128/MCB.20.3.1001-1007.2000 10629057 (Pubitemid 30044237)
17. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Kawai H, Wiederschain D, Yuan ZM, Mol Cell Biol 2003 23 14 4939 4947 10.1128/MCB.23.14.4939-4947.2003 12832479 (Pubitemid 36793339)
18. Functions of MDMX in the modulation of the p53-response. Lenos K, Jochemsen AG, J Biomed Biotechnol 2011 2011 876173 21541195
19. Mutual dependence of MDM2 and MDMX in their functional inactivation of p53. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM, J Biol Chem 2002 277 22 19251 19254 10.1074/jbc.C200150200 11953423 (Pubitemid 34967428)
20. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M, Proc Natl Acad Sci U S A 2003 100 21 12009 12014 10.1073/pnas.2030930100 14507994 (Pubitemid 37271506)
21. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. Sharp DA, Kratowicz SA, Sank MJ, George DL, J Biol Chem 1999 274 53 38189 38196 10.1074/jbc.274.53.38189 10608892 (Pubitemid 30026893)
22. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. Wang X, Wang J, Jiang X, J Biol Chem 2011 286 27 23725 23734 10.1074/jbc.M110.213868 21572037
23. Hdmx recruitment into the nucleus by Hdm2 is essential for its ability to regulate p53 stability and transactivation. Migliorini D, Danovi D, Colombo E, Carbone R, Pelicci PG, Marine JC, J Biol Chem 2002 277 9 7318 7323 10.1074/jbc.M108795200 11744695 (Pubitemid 34953126)
24. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Bartel F, Schulz J, Bohnke A, Blumke K, Kappler M, Bache M, Schmidt H, Wurl P, Taubert H, Hauptmann S, Int J Cancer 2005 117 3 469 475 10.1002/ijc.21206 15906355 (Pubitemid 41429571)
25. Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma. Ohnstad HO, Castro R, Sun J, Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza-Zepeda LA, Myklebost O, Cancer 2012 119 5 1013 1022 23165797
26. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both SNP309 and MDM2 amplification in sarcomagenesis. Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, Zumstein-Mecker S, Choong PF, Dickinson I, Crowe P, et al. Clin Cancer Res 2011 17 3 416 426 10.1158/1078-0432.CCR-10-2050 21159888
27. Aberrant expression of HDMX proteins in tumor cells correlates with wild-type p53. Ramos YF, Stad R, Attema J, Peltenburg LT, van der Eb AJ, Jochemsen AG, Cancer Res 2001 61 5 1839 1842 11280734 (Pubitemid 32691995)
28. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. Barakat K, Mane J, Friesen D, Tuszynski J, J Mol Graph Model 2010 28 6 555 568 10.1016/j.jmgm.2009.12.003 20056466
29. MDM2/MDMX inhibitor peptide: WO2008106507. Macchiarulo A, Pellicciari R, Expert Opin Ther Pat 2009 19 5 721 726 10.1517/13543770902755137 19441944
30. Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. Phan J, Li Z, Kasprzak A, Li B, Sebti S, Guida W, Schonbrunn E, Chen J, J Biol Chem 2010 285 3 2174 2183 10.1074/jbc.M109.073056 19910468
31. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Pazgier M, Liu M, Zou G, Yuan W, Li C, Li J, Monbo J, Zella D, Tarasov SG, Lu W, Proc Natl Acad Sci U S A 2009 106 12 4665 4670 10.1073/pnas.0900947106 19255450
32. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, Holak TA, Cell Cycle 2009 8 8 1176 1184 10.4161/cc.8.8.8185 19305137
33. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present). Zak K, Pecak A, Rys B, Wladyka B, Domling A, Weber L, Holak TA, Dubin G, Expert Opin Ther Pat 2013 23 4 425 448 10.1517/13543776.2013.765405 23374098
34. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Li Q, Lozano G, Clin Cancer Res 2013 19 1 34 41 10.1158/1078-0432.CCR-12-0053 23262034
35. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, Di Lello P, Fry D, Garvie C, Huang KS, et al. Proc Natl Acad Sci U S A 2012 109 29 11788 11793 10.1073/pnas.1203789109 22745160
36. GeneScreen: a program for high-throughput mutation detection in DNA sequence electropherograms. Carr IM, Camm N, Taylor GR, Charlton R, Ellard S, Sheridan EG, Markham AF, Bonthron DT, J Med Genet 2011 48 2 123 130 10.1136/jmg.2010.082081 21037276
37. Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms. Stad R, Little NA, Xirodimas DP, Frenk R, van der Eb AJ, Lane DP, Saville MK, Jochemsen AG, EMBO Rep 2001 2 11 1029 1034 10.1093/embo-reports/kve227 11606419 (Pubitemid 33130611)
38. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, et al. Cancer Res 2007 67 14 6626 6636 10.1158/0008-5472.CAN-07-0584 17638873 (Pubitemid 47105508)
39. Can MDM2 and CDK4 make the diagnosis of well differentiated/ dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours. Aleixo PB, Hartmann AA, Menezes IC, Meurer RT, Oliveira AM, J Clin Pathol 2009 62 12 1127 1135 10.1136/jcp.2009.070201 19946100
40. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma. Oda Y, Sakamoto A, Satio T, Kawauchi S, Iwamoto Y, Tsuneyoshi M, Mod Pathol 2000 13 9 994 1004 10.1038/modpathol.3880180 11007040